Stoke Therapeutics, Inc.
STOK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for STOK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · STOK
Stoke Therapeutics is a clinical-stage biotechnology company focused on developing antisense oligonucleotide therapies for genetic diseases, with its lead candidate zorevunersen in Phase 3 trials for Dravet syndrome.
Key risk: Clinical trial failure
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.04B
Cash Runway
15.5 moLead Asset
stk-002 (Phase 1)
Next Catalyst
Phase3_Topline · Oct 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for Stoke Therapeutics, Inc..
Stoke Therapeutics is a clinical-stage biotechnology company focused on developing antisense oligonucleotide therapies for genetic diseases, with its lead candidate zorevunersen in Phase 3 trials for Dravet syndrome.
- Lead product candidate zorevunersen is being evaluated in a Phase 3 study (EMPEROR) for Dravet syndrome [catalyst].
- Cash and equivalents of $110.0M as of 2026-06-30 [sec].
- Total revenue of $9.3M and net loss of $61.6M for the six months ended June 30, 2026 [sec].
- Accumulated deficit of $609.3M as of June 30, 2026 [sec_mda].
- Management expects existing cash to fund operations through potential U.S. commercialization of zorevunersen in early 2028 [sec_mda].
What works
- Zorevunersen has advanced to a Phase 3 randomized, double-blind, sham-controlled study, indicating prior clinical data supported further development [catalyst].
- The company has a strategic collaboration with Biogen, which may provide additional resources and expertise [sec].
- Cash runway is projected to extend through early 2028, covering a key catalyst readout [sec_mda].
What to weigh
- Stoke has an accumulated deficit of $609.3M and expects to continue incurring net losses for the foreseeable future [sec_mda].
- The company has no approved products and has not generated any product revenue to date [sec_mda].
- Additional financing will be required to advance clinical programs and fund operations, with no guarantee of raising capital on favorable terms [sec_mda].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2028-10-01 · Phase3_Topline — Topline results from the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome are expected.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — Phase 3 topline results for zorevunersen are pivotal; negative data could halt development [catalyst].
- Capital needs — Company expects to need additional financing to sustain operations beyond early 2028 [sec_mda].
- No approved products — Stoke has no commercial products and has never generated product revenue [sec_mda].
- Regulatory uncertainty — Zorevunersen requires FDA approval; regulatory path and timeline are uncertain [sec].
What to watch
- Phase 3 topline data for zorevunersen expected around October 2028 [catalyst].
- Cash burn rate and any new financing or partnership announcements [sec_mda].
- Regulatory interactions and potential filing for zorevunersen [sec].
- Updates on the Biogen collaboration and any milestone payments [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Stoke Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Stoke Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
15.5 months
D/E 0.14 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~763d
0 buys · 40 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$2.20B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 5,623,525 | $183.1M |
| blackrock, inc. | 5,385,714 | $175.4M |
| fmr llc | 5,383,666 | $175.3M |
| lynx1 capital management lp | 4,763,673 | $155.1M |
| vanguard capital management llc | 4,711,206 | $153.4M |
| morgan stanley | 3,423,280 | $111.5M |
| baker bros. advisors lp | 3,336,697 | $108.6M |
| toronto dominion bank | 3,173,258 | $103.3M |
| wellington management group llp | 3,095,700 | $100.8M |
| bvf inc/il | 2,547,557 | $82.9M |
Showing top 10 of 196 institutional holders of Stoke Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 25.8%
- Days to cover
- 13.3
- Shares short
- 12,818,891
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
STOK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Stoke Therapeutics, Inc.?
Stoke Therapeutics is a clinical-stage biotechnology company focused on developing antisense oligonucleotide therapies for genetic diseases, with its lead candidate zorevunersen in Phase 3 trials for Dravet syndrome.
What is Stoke Therapeutics, Inc.'s lead drug candidate?
Stoke Therapeutics, Inc.'s most advanced tracked candidate is stk-002 (Phase 1) for Autosomal dominant optic atrophy (ADOA).
What is Stoke Therapeutics, Inc.'s next catalyst?
Stoke Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva" — expected October 1, 2028.
Who is the CEO of Stoke Therapeutics, Inc.?
Mr. Ian F. Smith A.C.A., C.P.A. is the chief executive officer of Stoke Therapeutics, Inc. (STOK).
Where is Stoke Therapeutics, Inc. headquartered?
Stoke Therapeutics, Inc. (STOK) is headquartered in Bedford, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.